IRIS
BARONE, PAOLO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 1.748
NA - Nord America 1.736
EU - Europa 1.437
SA - Sud America 301
AF - Africa 48
Continente sconosciuto - Info sul continente non disponibili 5
Totale 5.275
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.660
SG - Singapore 997
RU - Federazione Russa 763
CN - Cina 378
BR - Brasile 251
HK - Hong Kong 138
DE - Germania 126
VN - Vietnam 123
FI - Finlandia 112
IT - Italia 93
NL - Olanda 76
IE - Irlanda 63
UA - Ucraina 58
GB - Regno Unito 52
CA - Canada 41
SE - Svezia 38
MX - Messico 27
IN - India 21
AR - Argentina 20
FR - Francia 20
ZA - Sudafrica 15
TR - Turchia 14
BD - Bangladesh 11
CI - Costa d'Avorio 11
ES - Italia 11
JP - Giappone 11
PL - Polonia 10
ID - Indonesia 9
EC - Ecuador 7
VE - Venezuela 7
IQ - Iraq 6
CO - Colombia 5
IL - Israele 5
UZ - Uzbekistan 5
DZ - Algeria 4
EU - Europa 4
PK - Pakistan 4
UY - Uruguay 4
AE - Emirati Arabi Uniti 3
CL - Cile 3
EG - Egitto 3
JO - Giordania 3
MA - Marocco 3
BY - Bielorussia 2
CZ - Repubblica Ceca 2
DO - Repubblica Dominicana 2
ET - Etiopia 2
GM - Gambi 2
GT - Guatemala 2
KG - Kirghizistan 2
LT - Lituania 2
MD - Moldavia 2
OM - Oman 2
PY - Paraguay 2
SA - Arabia Saudita 2
SN - Senegal 2
TL - Timor Orientale 2
YE - Yemen 2
AD - Andorra 1
BE - Belgio 1
BS - Bahamas 1
CM - Camerun 1
CU - Cuba 1
GA - Gabon 1
GE - Georgia 1
GY - Guiana 1
HT - Haiti 1
HU - Ungheria 1
IR - Iran 1
IS - Islanda 1
KE - Kenya 1
KW - Kuwait 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
LK - Sri Lanka 1
LV - Lettonia 1
ML - Mali 1
NP - Nepal 1
PE - Perù 1
PH - Filippine 1
RO - Romania 1
SI - Slovenia 1
SV - El Salvador 1
TH - Thailandia 1
TJ - Tagikistan 1
TN - Tunisia 1
TZ - Tanzania 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 5.275
Salva come PNG Salva come JPEG
Città #
Singapore 436
Moscow 178
Chandler 170
Santa Clara 159
Hong Kong 136
Ashburn 131
Beijing 128
Jacksonville 100
Millbury 73
Amsterdam 70
Princeton 70
Los Angeles 65
Nanjing 60
Ho Chi Minh City 52
Munich 47
Boston 45
Dallas 33
Wilmington 30
Buffalo 29
Nanchang 29
The Dalles 29
Seattle 26
New York 25
Helsinki 22
São Paulo 22
Turku 21
Hanoi 20
Ottawa 20
San Jose 20
Redondo Beach 19
Houston 16
Mexico City 16
Norwalk 15
Naples 13
Washington 13
Columbus 12
Rome 12
Boardman 11
Brooklyn 11
Tokyo 11
Ankara 10
Chicago 10
Denver 10
Kunming 10
Stockholm 10
Belo Horizonte 9
Da Nang 9
Falkenstein 9
Montreal 9
Napoli 9
London 8
Pune 8
Shanghai 8
Brasília 7
Falls Church 7
Frankfurt am Main 7
Jiaxing 7
Shenyang 7
Tianjin 7
Orem 6
Atlanta 5
Hangzhou 5
Manchester 5
Poplar 5
Rio de Janeiro 5
San Francisco 5
Tashkent 5
Thái Bình 5
Toronto 5
Bexley 4
Changsha 4
Chennai 4
Hebei 4
Hefei 4
Kronberg 4
Montevideo 4
Porto Alegre 4
Santo André 4
Secaucus 4
Tampa 4
Vinh 4
Warsaw 4
Amman 3
Ann Arbor 3
Baghdad 3
Bauru 3
Betim 3
Calgary 3
Changchun 3
Charlotte 3
Curitiba 3
Dublin 3
Fortaleza 3
Guangzhou 3
Guarujá 3
Haiphong 3
Indiana 3
Istanbul 3
Karachi 3
Manaus 3
Totale 2.713
Salva come PNG Salva come JPEG
Nome #
Imaging of dopaminergic dysfunction with [123I]FP-CIT SPECT in early-onset parkin disease. 137
Short-term continuous infusion of apomorphine hydrochloride for treatment of Huntington's chorea: A double blind, randomized cross-over trial 123
Gender differences in non-motor symptoms in early, drug naïve Parkinson's disease 123
Serum epidermal growth factor predicts cognitive functions in early, drug-naive Parkinson's disease patients. 122
Reduced striatal [123I]FP-CIT binding in SCA2 patients without parkinsonism 116
Loss of cutaneous large and small fibers in naive and l-dopa-treated PD patients 111
Mild cognitive impairment in drug-naive patients with PD is associated with cerebral hypometabolism. 105
MR imaging index for differentiation of progressive supranuclear palsy from Parkinson disease and the Parkinson variant of multiple system atrophy. 103
A neuropsychological longitudinal study in Parkinson's patients with and without hallucinations. 99
Cerebellar and pyramidal dysfunctions, palpebral ptosis and weakness as presenting symptoms of PARK-2. 99
Freezing of gait and executive functions in patients with Parkinson's disease. 95
Diffusion-weighted imaging in multiple system atrophy: a comparison between clinical subtypes. 95
Anhedonia and cognitive impairment in Parkinson's disease: Italian validation of the Snaith-Hamilton Pleasure Scale and its application in the clinical routine practice during the PRIAMO study. 94
Functional involvement of central cholinergic circuits and visual hallucinations in Parkinson's disease. 90
PINK1 heterozygous rare variants: prevalence, significance and phenotypic spectrum. 89
RNA analysis of consensus sequence splicing mutations: implications for the diagnosis of Wilson disease. 88
No evidence of association between CAG expansions and essential tremor in a large cohort of italian patients 87
Parkinsonism and essential tremor in a family with pseudo-dominant inheritance of PARK2: an FP-CIT SPECT study. 87
Is arginine test a reliable tool for differential diagnosis of multiple system atrophy? 87
Dopamine agonist-based strategies in the treatment of Parkinson's disease. 86
Nitric oxide-hemoglobin interaction: a new biochemical hypothesis for signal changes in fMRI 86
The arginine growth hormone stimulation test in bradykinetic-rigid parkinsonisms 85
A two-year follow-up study of executive dysfunctions in parkinsonian patients with freezing of gait at on-state. 83
Comparison between a dual-head and a brain-dedicated SPECT system in the measurement of the loss of dopamine transporters with [123I]FP-CIT. 81
Frontal dysfunction contributes to the genesis of hallucinations in non-demented Parkinsonian patients. 81
Relationship between depression and cognitive dysfunctions in Parkinson's disease without dementia. 81
The PRIAMO study: background, methods and recruitment. 80
Perspectives on recent advances in the understanding and treatment of Parkinson's disease. 80
Differential neuropsychological profiles in Parkinsonian patients with or without vascular lesions. 77
HOMER1 promoter analysis in Parkinson's disease: association study with psychotic symptoms. 76
Safety and efficacy of perampanel in advanced Parkinson's disease: a randomized, placebo-controlled study. 76
Vestibular impairment and adaptive postural imbalance in parkinsonian patients with lateral trunk flexion 76
Growth hormone stimulation tests in the differential diagnosis of Parkinson's disease. 76
Multiple system atrophy is distinguished from idiopathic Parkinson's disease by the arginine growth hormone stimulation test 75
Olfactory dysfunction in Parkinsonism caused by PINK1 mutations. 75
Linkage exclusion in Italian families with hereditary essential tremor. 75
Depression rating scales in Parkinson's disease: critique and recommendations. 74
Pain as a nonmotor symptom of Parkinson disease: evidence from a case-control study. 71
Clinical and neurological abnormalities in adult celiac disease. 68
HOMER1 promoter analysis in parkinson's disease: association study with psychotic symptoms 67
Dopamine receptor agonists and depression in Parkinson's disease. 67
Dopamine mediated responses in 6-OH-DA lesioned rats involve changes of the signal transduction. 66
Dopa-responsive pseudo-orthostatic tremor in parkinsonism. 65
Red flags for multiple system atrophy. 65
Amitriptyline as a prophylactic for migraine in children. 64
Prevalence of nonmotor symptoms in Parkinson's disease in an international setting; study using nonmotor symptoms questionnaire in 545 patients. 64
Behavioural sensitization in 6-OHDA lesioned rats is related to compositional changes of the AP-1 transcription factor: evidence for induction of FosB-related and JunD-related proteins 63
Nitrite- and peroxide-dependent oxidation pathways of dopamine: 6-nitrodopamine and 6-hydroxydopamine formation as potential contributory mechanisms of oxidative stress- and nitric oxide-induced neurotoxicity in neuronal degeneration 63
No evidence of association between CAG expansions and essential tremor in a large cohort of italian patients 62
Pergolide monotherapy in the treatment of early PD. A randomized, controlled study. 61
The status of dopamine nerve terminals in Parkinson\'s disease and essential tremor: a PET study with the tracer [11-C]FE-CIT. 61
COMT inhibition with tolcapone in the treatment algorithm of patients with Parkinson's disease (PD): relevance for motor and non-motor features. 61
Rivastigmine versus placebo in hyperhomocysteinemic Parkinson's disease dementia patients. 60
Apoptotic mechanisms in mutant LRRK2-mediated cell death. 59
International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson's disease: the NMSQuest study. 59
Subclinical sensory abnormalities in unaffected PINK1 heterozygotes. 58
Apparent diffusion coefficient of the superior cerebellar peduncle differentiates progressive supranuclear palsy from Parkinson's disease. 58
The metric properties of a novel non-motor symptoms scale for Parkinson's disease: Results from an international pilot study. 58
Growth hormone stimulation tests in the differential diagnosis of Parkinson's disease. 58
Stimulation of growth hormone release in multiple system atrophy, Parkinson's disease and idiopathic cerebellar ataxia. 57
How many parkinsonian patients are suitable candidates for deep brain stimulation of subthalamic nucleus? Results of a questionnaire. 56
The effect of pramipexole on mood and motivational symptoms in Parkinson's disease: a meta-analysis of placebo-controlled studies. 56
Headache in children, an epidemiological study. 53
The PRIAMO study: A multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease. 53
Neurotransmission in Parkinson's disease: beyond dopamine. 52
Cognitive dysfunctions and pathological gambling in patients with Parkinson's disease. 50
Progression of multiple system atrophy (MSA): a prospective natural history study by the European MSA Study Group (EMSA SG). 46
The FRAGAMP study: environmental and genetic factors inParkinson's disease, methods and clinical features. 46
Impaired transmethylation potential in Parkinson's disease patients treated with L-Dopa. 43
Non-motor symptoms in atypical and secondary parkinsonism: the PRIAMO study. 41
null 12
Totale 5.316
Salva come PNG Salva come JPEG
Categoria #
all - tutte 18.414
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 18.414
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202148 0 0 0 0 0 0 11 2 13 2 19 1
2021/2022319 3 0 0 4 0 9 1 12 67 12 52 159
2022/2023410 73 35 17 25 46 33 0 38 57 66 16 4
2023/2024321 7 38 32 35 27 53 2 32 0 10 73 12
2024/20251.726 101 82 6 9 86 133 174 118 71 170 638 138
2025/20261.946 348 196 306 293 607 109 87 0 0 0 0 0
Totale 5.316